ScoreWhy is Ryvu Therapeutics SA ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 8.88% and Operating profit at -215.67% over the last 5 years
3
Flat results in Sep 25
- INTEREST(HY) At PLN 5.04 MM has Grown at 155.91%
- ROCE(HY) Lowest at -95.35%
- NET SALES(Q) At PLN 14.92 MM has Fallen at -14.7%
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -12.55%, its profits have fallen by -30.8%
5
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -12.55% returns in the last 1 year, the stock has also underperformed Poland WIG in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Ryvu Therapeutics SA for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ryvu Therapeutics SA
-12.55%
-1.45
42.16%
Poland WIG
27.62%
1.38
19.95%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.88%
EBIT Growth (5y)
-215.67%
EBIT to Interest (avg)
-75.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.31
EV to EBIT
-3.48
EV to EBITDA
-3.73
EV to Capital Employed
75.89
EV to Sales
7.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2178.87%
ROE (Latest)
-129.70%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
NET PROFIT(HY)
Higher at PLN -54.04 MM
RAW MATERIAL COST(Y)
Fallen by -13.96% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -92.69 %
DEBTORS TURNOVER RATIO(HY)
Highest at 2.71 times
OPERATING PROFIT(Q)
Highest at PLN -26.82 MM
EPS(Q)
Highest at PLN -1.07
-10What is not working for the Company
INTEREST(HY)
At PLN 5.04 MM has Grown at 155.91%
ROCE(HY)
Lowest at -95.35%
NET SALES(Q)
At PLN 14.92 MM has Fallen at -14.7%
Here's what is working for Ryvu Therapeutics SA
Net Profit
Higher at PLN -54.04 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (PLN MM)
Operating Profit
Highest at PLN -26.82 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (PLN MM)
EPS
Highest at PLN -1.07
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (PLN)
Debt-Equity Ratio
Lowest at -92.69 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 2.71 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -13.96% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at PLN 2.86 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (PLN MM)
Here's what is not working for Ryvu Therapeutics SA
Interest
At PLN 5.04 MM has Grown at 155.91%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (PLN MM)
Net Sales
At PLN 14.92 MM has Fallen at -14.7%
over average net sales of the previous four periods of PLN 17.49 MMMOJO Watch
Near term sales trend is very negative
Net Sales (PLN MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
